The Elucigene TRP F Plus
4 high risk mutations
Reliable and accurate detection
Simple, easy to use protocol
Venous thromboembolisms (VTE) occurs in 1-2 individuals per 1000 and there are approximately 10 million cases worldwide. There are between 100,000 and 300,000 VTE related deaths in the US, and 544,000 in Europe each year, which has resulted in a major health economic burden. There are many factors that increase the risk of thrombophilia such as surgery, pregnancy, the use of oral contraceptives and prolonged immobilisation (economy class syndrome).
Genetic factors also contribute to an individual’s risk of VTE. Factor V Leiden is the most common inherited form of thrombophilia, occurring in 3.8% of the general US and European population in a heterozygous state. Heterozygous individuals are 7 fold more likely to develop a VTE, while homozygous individuals have an 80 fold increased risk Prothrombin thrombophilia is the second most common form and occurs in approximately 1 in 50 people in the Caucasian US and European population Mutations in MTHFR are associated with elevated homocysteine levels, an increased risk of blood clots, pregnancy loss or neural tube defects in offspring.
- TRP F plus : Factor V Leiden, Factor II, MTHR (677 C>T/1298 A>)
This kit offers detection of the four most relevant mutations implicated in an increased risk of developing venous thromboembolism.
- Simple to use
- Reagents ready to use in a single multiplexed tube – just add DNA
- Minimal hands on time
- Low failure rates
- Rapid turnaround time
- Easy to interpret
- Optimally balanced primers
- Test distinguishes between heterozygous and homozygous individuals
- Assay validated on multiple thermal cyclers and ABI genetic analysers